Director Declaration

RNS Number : 8922Y

Advanced Oncotherapy PLC

28 August 2018

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Confirmation of board appointments

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, further to the Company's announcement of 2 July 2018, Dr. Peter Sjostrand, Mr. Gabriel Urwitz, Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang have been appointed as Non-Executive Directors, with immediate effect.

Information required by Rule 17 and Schedule Two paragraph (g) of the AIM Rules are disclosed below:

Peter Sjostrand - Non-Executive Director & Vice-Chairman

Peter Sigurd Ivar Sjostrand, aged 72, owns no shares in the Company. Mr Sjostrand has a long career as an independent Non-Executive Director for a number of public and private companies within the Healthcare, Industrial and Financial areas. He has been a director of the following companies during the previous five years:

Current directorships	Previous directorships in the last 5 years
Active Biotech AB	Acturum Life Sciences AB
Acturum Chemical Library AB	American Scandinavian Foundation
Acturum Development AB	Calmark Sweden AB
Acturum Real Estate AB	Prebona AB
Acturum Tox AB	Slutsteget nr 26 AB
Bostadsrattsforeningen Skatan nr 6
Bostadsrattsforeningen Vintergatan 1
Byggnads AB S:t Erik
Stiftelsen Oscar Hirschs Minne
Materulla AB
Peter Sjostrand AB
Ringens Varv AB
Ringens Varv i Marstrand AB
SAMF Sweden AB

Gabriel Urwitz - Non-Executive Director

Bo Gabriel Urwitz, aged 68, has an extensive background in industry and finance and has been involved with a large number of successful listed and private companies during his career. Gabriel co-founded Segulah Advisors AB in 1994 and was adjunct professor of financial economics at the Stockholm School of Economics from 1977 until 2002. Mr Urwitz is a Director of AB Segulah, which owns 3.84% of the Company. A consortium led by AB Segulah owns 8.03%. Mr Urwitz has been a director of the following companies during the previous five years:

Current directorships	Previous directorships in the last 5 years
Aktiebolaget Segulah	Almondy Aktibolag
Bostadsrattsforeningen Karlavagen AB	Almondy Group Holding AB
GridZupport Sweden AB	ANordiska VA Teknik Holding AB
Lokaltidningen Mitt I Stockholm AB	DOCU Nordic Group Holding AB
Longtide Limited	DOCU Nordic Holding AB
Mitt i Investment Holding AB	Dacke Industri Holding AB
Mitt i TopCo AB	Etraveli AB
Optolexia AB	eTRAVELi AB (publ)
Paideia Foundation	GRIDZupport AB*
PowerTender AB	HerMed Group Holding AB
Segulah Advisor AB	HerMed Holding AB
Segulah Citrata Holding AB	Joy Boy Aktiebolag
Segulah Crispum Holding AB	Joy Shop Aktiebolag
Segulah III Investment AB	LiRe AB
Segulah IV Investment AB	Mitt i Investment AB
Segulah Serrata Holding AB	Mitt i Investment Holding AB
Segulah V F&F AB	Mitt i TopCo AB
Segulah V Investment AB	PMC Hydraulics Group AB
Segulah Venture AB	Sandbacken Invest Group Holding AB
Semantix	Sandbacken Invest Holding AB
Semantix Holding AB	Segulah Kemetyl Finance AB
Semantix International AB	Segulah Norway Investment AB
Semantix International Group AB	Segulah PMC Finance AB
Spatial Transcriptomics Holding AB	Semantix Group Holding AB
Spatial Transcriptomics AB	Semantix Holding AB
Svangremmen AB	Semantix International AB
Swedish House of Finance	Semantix International Group AB
Trioxytech AB	Teknikmagasinet Nordic Group Holding AB
Zengun AB	Zengun Group Holding AB
Zengun Group Holding AB	Zengun Holding AB
Zengung Holding AB

Mr Urwitz is a deputy member of the board of GridZupport Sweden AB which began bankruptcy proceedings on 12 December 2017; on 27 May 2018 the assets and liabilities of GridZupport were acquired by Segulah Venture AB.

Mr Urwitz was a director of Gota Bank, resigning in August 1992. The holding company of Gota Bank, Gota AB, was declared bankrupt in September 1992.

Mr Urwitz was also a member of the board of Segulah Norway Investment AB when it entered into liquidation on 15 September 2017.

Mr. Chunlin Han - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, Chunlin Han, aged 25, is a Director of Hangzhou Ruilin Ynovo Investment Partners Ltd. which wholly owns Liquid Harmony Limited. Mr Han is an executive Director of Liquid Harmony Ltd and serves as Head of Investment and Financing for Realcan Pharmaceuticals Co. Ltd. Mr Han has been a director of the following companies during the previous five years:

Current directorships	Previous directorships in the last 5 years
Hangzhou Hengkang Investment Partnership (limited partnership)	Ruiheng (Shanghai) Information Technology Co. Ltd.
Hangzhou Hengyi Investment Partnership (limited partnership)
Hangzhou Hengyue Investment Partnership (limited partnership)
Hangzhou Ronggu Investment Management Co. Ltd
Hangzhou Ruilin Ynovo Investment Partnership (Limited Partners) Hangzhou Equilibrium Nine Investment Management Co. Ltd
Huacan Dental Medical Holdings Co Ltd
Jinlong Haiyue Investment Co Ltd
Jinlong Haiyue Medical Technology Co Ltd
Liquid Harmony Limitedtd
Qingdao HengXin Hospital Management Co. Ltd
Qingdao Lekang Jinyue Finance Leasing
Ruimai (Yantai) Medical Diagnosis Co. Ltd.
Rushan Henghua Pharmaceutical Co Ltd.
Rushan Huaxin Heng'an Finance Leasing Co Ltd
Shandong NuoZhou Medical Investment Co. Ltd
Shandong Realcan Medical Testing Co. Ltd.
Shandong Yuehui Medical Technology Co. Ltd
Shangdon Realcan Pharmaceutical Shanghai Co Ltd
Shanghai Fengyu Asset Management Co. Ltd.
Shanghai Henghua Health Consulting Co. Ltd
Shanghai Xiaoka Information Technology Co. Ltd
Shanghai Xinxin Ronghua Investment Co. Ltd
Shanghai Yourong Lincheng Pharmaceutical Industry Investment Co. Ltd.
Shenzhen Qianhai Ruifeng Commercial Factoring Co. Ltd
Shenzhen Qianhai Ruitong Supply Chain Management Co. Ltd
Tianji Health Medical Technology Co Ltd Shanghai Subsidiary
Weihai Hengjian Hospital Management Co Ltd
Zhejiang Equilibrium Nine Medical Equipment Co. Ltd

Mrs. RenHua Zhang - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, RenHua Zhang, aged 52, owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Mrs Zhang is the co-Founder, CEO, and Vice Chairman of the board of Realcan Pharmaceutical Co. Ltd, a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals. Mrs Zhang has been a director of the following companies during the previous five years:

Current directorships	Previous directorships in the last 5 years
Realcan Pharmaceutical Co., Ltd.	None
Shandon Ruikang'anlai Medical Technology Co. Ltd
Shandong Cheng'en Investment Co. Ltd
Shandong Multidisciplinary Treatment
Shandong Realcan Pharmaceutical Distribution Co. Ltd
Shandong Ruixiang Stomatological Dental Hospital Co. Ltd.
Yantai Ruiyou Investment Co., Ltd

Dr Yuelong Huang - Non-Executive Director

Representing Liquid Harmony Ltd which owns 29.9% of the Company, Yuelong Huang, aged 41 owns no shares in the Company although is considered to be acting in concert with Liquid Harmony Ltd. Scientist by background, Mr Huang serves as General Manager of Medical Technology Department of Realcan Pharmaceuticals Co. Ltd where he is responsible for all M&A activities and medtech R&D/manufacturing. Mr Huang has been a director of the following companies during the previous five years:

Current directorships	Previous directorships in the last 5 years
Hangzhou HongHui Electronic Technology Co., Ltd	Jiangyin Sino-German Technology Trasfer Centre
Hangzhou Tuobaba Technology Co. Ltd	Suqian Zhilong Photoelectric Co Ltd
Hangzhou WanMengTe Technology Co. Ltd
Hangzhou Ynovo Investment Management Co. Ltd
Jiangyin BinLong Technology Co. Ltd

Save as set out in this announcement, there are no further details to be disclosed under Rule 17 or Schedule 2(g) of the AIM Rules for Companies in respect of the appointments set out above.

For further information, please contact:

Advanced Oncotherapy Plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / Ed Thomas	Tel: [phone]
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RDNPRMLTMBJTMPP